| WB | DB: 1/500 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Claudin-2, SP82, CLDN2 |
| Entrez GeneID | 9075 |
| WB Predicted band size | 24.5kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | This CLDN2 Antibody is generated from rabbits immunized with a KLH conjugated synthetic phosphopeptide corresponding to amino acid residues surrounding Y224 of human CLDN2. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于Phospho-CLDN2(Y224)抗体的参考文献示例(注：以下内容为模拟示例，实际文献需根据具体数据库查询)：
1. **文献名称**：*Phosphorylation of Claudin-2 at Tyrosine 224 Modulates Intestinal Barrier Function*
**作者**：Suzuki T, et al.
**摘要**：该研究通过Phospho-CLDN2(Y224)抗体证实，酪氨酸224位点的磷酸化可增强claudin-2的通道功能，从而影响肠道上皮细胞的通透性，并可能参与炎症性肠病的病理过程。
2. **文献名称**：*Src Kinase-Induced Phosphorylation of CLDN2 Regulates Renal Tubular Acidosis*
**作者**：Rahner C, et al.
**摘要**：研究发现，在肾脏上皮细胞中，Src激酶介导的CLDN2酪氨酸224位点磷酸化可改变紧密连接结构，导致肾小管酸中毒。研究通过特异性抗体验证了磷酸化修饰的定位及功能。
3. **文献名称**：*Role of CLDN2 Phosphorylation in Hepatocellular Carcinoma Metastasis*
**作者**：Wang L, et al.
**摘要**：利用Phospho-CLDN2(Y224)抗体进行免疫组化分析，发现肝癌组织中该位点的磷酸化水平升高，与肿瘤侵袭性和患者预后不良相关，提示其作为潜在治疗靶点。
4. **文献名称**：*Development and Validation of a Phospho-Specific Antibody for CLDN2 (Y224)*
**作者**：Zhang Y, et al.
**摘要**：该文献详细描述了Phospho-CLDN2(Y224)抗体的制备流程，并通过Western blot和免疫荧光验证其特异性，为后续研究提供可靠工具。
(注意：以上文献为假设性示例，实际引用需查询PubMed、Web of Science等数据库获取具体信息。)
**Background of Phospho-CLDN2(Y224) Antibody**
The Phospho-CLDN2(Y224) antibody is a specialized tool designed to detect claudin-2 (CLDN2) when phosphorylated at tyrosine residue 224. Claudin-2 is a member of the claudin family, integral membrane proteins critical for forming tight junctions that regulate paracellular permeability and maintain cell polarity in epithelial and endothelial tissues. CLDN2 is particularly associated with cation-selective channels and is highly expressed in tissues like the kidney, liver, and intestine.
Phosphorylation at Y224 is a post-translational modification implicated in modulating CLDN2 function. This modification may influence tight junction dynamics, cellular signaling, or interactions with other proteins, such as kinases or scaffolding molecules. Dysregulation of CLDN2 has been linked to pathological conditions, including cancer progression, fibrosis, and inflammatory diseases, where altered phosphorylation status could affect barrier integrity or promote cell migration.
The Phospho-CLDN2(Y224) antibody enables researchers to study CLDN2 activation or localization under conditions like inflammation, hypoxia, or growth factor stimulation. It is commonly used in techniques like Western blotting, immunofluorescence, or immunohistochemistry to assess phosphorylation-dependent changes in cellular models or clinical samples. Validation typically includes testing in CLDN2-knockout systems or phospho-peptide competition assays to confirm specificity. Understanding CLDN2 phosphorylation provides insights into its role in health and disease, making this antibody valuable for exploring epithelial barrier regulation and therapeutic targeting.
×
